Penumbra, Inc. (NYSE: PEN) is a Healthcare company (Medical - Devices) with a market capitalization of $12.6B. The Maz Rating grades it against the other companies in its sector.
Penumbra, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $319.11, Penumbra, Inc. trades at 80.1x trailing earnings, 8.1x sales and 7.9x book value, with an EV/EBITDA of 54.7. Over the last twelve months it generated about $1.6B of revenue and $157M of net income. It runs a gross margin of 68.0%, an operating margin of 12.1% and a net margin of 10.1%. It shows return on equity of 10.4%, return on invested capital of 7.9% and a free cash flow yield of 1.6%. On the balance sheet: a debt-to-equity ratio of 0.13 and a current ratio of 5.89. Over the past 52 weeks the share price ranged from $276.01 to $362.41, with a beta of 0.69.
Penumbra, Inc. does not currently pay a dividend.
22 Wall Street analyst ratings cover the stock: 9 Buy and 13 Hold, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Penumbra, Inc. (PEN) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 5.34% / 30% · Interest income / Revenue 1.49% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 5.34% / 33% · Receivables / Mkt Cap (36m) 1.55% / 49% · Interest income / Revenue 1.49% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 5.34% / 33.33% · Receivables / Mkt Cap (24m) 1.55% / 33.33% · Interest income / Revenue 1.49% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 32.3% / 33.33% · Receivables / Avg Assets (4Q) 9.82% / 33.33% · Interest income / Revenue 1.49% / 5% | Pass |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 33.3% / 33.33% · (Cash+Recv) / Total Assets 42.9% / 33.33% · Interest income / Revenue 1.49% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Penumbra, Inc. (PEN) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
Yes. Penumbra, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.49% of each dividend: Penumbra, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.